Publications by authors named "C S Milburn"
Impact of an alcohol withdrawal screening and treatment protocol for hospitalized patients.
J Subst Use Addict Treat
September 2024
Article Synopsis
- Alcohol Withdrawal Syndrome (AWS) poses serious risks for individuals with alcohol use disorder, making early detection essential in hospital settings, which led to the implementation of universal AUD screening using the PAWSS scale.
- A 6-year retrospective study compared patient outcomes before and after the introduction of a treatment protocol for AWS and involved 181 patients pre-protocol and 265 post-protocol.
- While the protocol did not significantly reduce hospital length of stay, it did lead to a notable decrease in the total benzodiazepine dose given and lower rates of delirium tremens among patients.
Introduction: Monthly injectable extended-release buprenorphine (XR-BUP) can address several systemic and individual barriers to consistent sublingual buprenorphine treatment for patients with opioid use disorder (OUD). Real-world evaluations of XR-BUP in the outpatient addiction treatment setting are limited. The purpose of this study was to compare 6-month treatment retention and urine drug tests between patients who initiated XR-BUP compared to those who were prescribed but did not initiate XR-BUP in a low-barrier addiction medicine specialty clinic.
View Article and Find Full Text PDFPurpose: The success of checkpoint blockade has led to a significant increase in the development of a broad range of immunomodulatory molecules for the treatment of cancer, including agonists against T-cell costimulatory receptors, such as OX40. Unlike checkpoint blockade, where complete and sustained receptor saturation may be required for maximal activity, the optimal dosing regimen and receptor occupancy for agonist agents is less well understood and requires further study.
Experimental Design: We integrated both preclinical and clinical biomarker data sets centered on dose, exposure, receptor occupancy, receptor engagement, and downstream pharmacodynamic changes to model the optimal dose and schedule for the OX40 agonist antibody BMS-986178 alone and in combination with checkpoint blockade.